decisionhealth Newsletters, Coder Pink Sheets - 2007 Issue 9 (September)
CMS cuts back on coverage for Procrit and other ESAs in new NCD
Subscribe or sign in to view the full article.
Article Overview
This article explains a CMS National Coverage Decision that narrows Medicare coverage for erythropoiesis stimulating agents used in anemia care. It is relevant to coding, billing, and reimbursement staff, especially in oncology and urology settings, because it discusses the types of clinical situations affected, the timing of the policy, and the need to review diagnosis coding and beneficiary notice considerations.
Why This Topic Matters
The policy change affects whether Medicare pays for the drug and its administration in certain anemia contexts, so coders and billers need to understand which claims may be impacted and when additional notice or referral planning may be considered.
What You Will Learn
- What CMS changed in its National Coverage Decision for erythropoiesis stimulating agents
- Which broad anemia and cancer-related situations are discussed in the coverage update
- Why the article highlights billing, administration, and beneficiary notice considerations
- How the policy timing and linked CMS/FDA references affect administrative follow-up
Who Should Read This
- Medical coders
- Billing staff
- Revenue cycle staff
- Oncology practices
- Urology practices
- Compliance staff
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com